Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Weight-adjusted neonatal 17OH-progesterone cutoff levels improve the efficiency of newborn screening for congenital adrenal hyperplasia.

Hayashi G, Faure C, Brondi MF, Vallejos C, Soares D, Oliveira E, Brito VN, Mendonca BB, Bachega TA.

Arq Bras Endocrinol Metabol. 2011 Nov;55(8):632-7.

2.

Neonatal 17-hydroxyprogesterone levels adjusted according to age at sample collection and birthweight improve the efficacy of congenital adrenal hyperplasia newborn screening.

Hayashi GY, Carvalho DF, de Miranda MC, Faure C, Vallejos C, Brito VN, Rodrigues AS, Madureira G, Mendonca BB, Bachega TA.

Clin Endocrinol (Oxf). 2017 Apr;86(4):480-487. doi: 10.1111/cen.13292. Epub 2017 Jan 23.

PMID:
27978607
3.

[Measurement of 17 OH progesterone in blood in Chilean newborns: antecedents for implementing a grogram for the neonatal detection of congenital adrenal hyperplasia].

Cattani A, Reyes ML, Azócar M, Soto J, Romeo E, Valdivia L, Poggi H, Foradori A.

Rev Med Chil. 2000 Oct;128(10):1113-8. Spanish.

PMID:
11349510
4.

Neonatal screening for congenital adrenal hyperplasia.

Barra CB, Silva IN, Pezzuti IL, Januário JN.

Rev Assoc Med Bras (1992). 2012 Jul-Aug;58(4):459-64. English, Portuguese.

5.

Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels.

Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A.

J Pediatr. 1997 Jan;130(1):128-33.

PMID:
9003862
6.

[Congenital adrenal hyperplasia newborn screening: Rio de Janeiro experience].

Cardoso CB, Fonseca AA, Oliveira Mde F, Pereira BB, Guimarães MM.

Arq Bras Endocrinol Metabol. 2005 Feb;49(1):112-9. Epub 2006 Mar 16. Portuguese.

7.

Antenatal corticosteroids and newborn screening for congenital adrenal hyperplasia.

King JL, Naber JM, Hopkin RJ, Repaske DR, Bailey L, Leslie ND.

Arch Pediatr Adolesc Med. 2001 Sep;155(9):1038-42.

PMID:
11529806
8.

A three-year follow-up of congenital adrenal hyperplasia newborn screening.

Pezzuti IL, Barra CB, Mantovani RM, Januário JN, Silva IN.

J Pediatr (Rio J). 2014 May-Jun;90(3):300-7. doi: 10.1016/j.jped.2013.09.007. Epub 2014 Feb 18.

9.

Neonatal screening for congenital adrenal hyperplasia in North-Eastern Italy: a report three years into the program.

Cavarzere P, Camilot M, Teofoli F, Tatò L.

Horm Res. 2005;63(4):180-6. Epub 2005 Apr 7.

PMID:
15818055
10.

Neonatal screening for congenital adrenal hyperplasia: experience and results in Argentina.

Gruñieiro-Papendieck L, Chiesa A, Mendez V, Prieto L.

J Pediatr Endocrinol Metab. 2008 Jan;21(1):73-8.

PMID:
18404975
11.

Neonatal screening program for congenital adrenal hyperplasia: adjustments to the recall protocol.

Gruñeiro-Papendieck L, Prieto L, Chiesa A, Bengolea S, Bossi G, Bergadá C.

Horm Res. 2001;55(6):271-7.

PMID:
11805430
12.

Newborn screening for congenital adrenal hyperplasia in Cuba: six years of experience.

González EC, Carvajal F, Frómeta A, Arteaga AL, Castells EM, Espinosa T, Coto R, Pérez PL, Tejeda Y, Del Río L, Segura MT, Almenares P, Robaina R, Fernández JL.

Clin Chim Acta. 2013 Jun 5;421:73-8. doi: 10.1016/j.cca.2013.02.020. Epub 2013 Feb 26.

PMID:
23481450
13.

Cutoff levels of 17-alpha-hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight.

van der Kamp HJ, Oudshoorn CG, Elvers BH, van Baarle M, Otten BJ, Wit JM, Verkerk PH.

J Clin Endocrinol Metab. 2005 Jul;90(7):3904-7. Epub 2005 Mar 29.

PMID:
15797960
14.
15.

Influence of spironolactone on neonatal screening for congenital adrenal hyperplasia.

Terai I, Yamano K, Ichihara N, Arai J, Kobayashi K.

Arch Dis Child Fetal Neonatal Ed. 1999 Nov;81(3):F179-83.

16.

Corrected 17-alpha-hydroxyprogesterone values adjusted by a scoring system for screening congenital adrenal hyperplasia in premature infants.

Lee JE, Moon Y, Lee MH, Jun YH, Oh KI, Choi JW.

Ann Clin Lab Sci. 2008 Summer;38(3):235-40.

PMID:
18715851
17.

Steroid profiling for congenital adrenal hyperplasia by tandem mass spectrometry as a second-tier test reduces follow-up burdens in a tertiary care hospital: a retrospective and prospective evaluation.

Seo JY, Park HD, Kim JW, Oh HJ, Yang JS, Chang YS, Park WS, Lee SY.

J Perinat Med. 2014 Jan;42(1):121-7. doi: 10.1515/jpm-2013-0154.

PMID:
23989111
18.

Ten-year evaluation of a Neonatal Screening Program for congenital adrenal hyperplasia.

Nascimento ML, Cristiano AN, Campos Td, Ohira M, Cechinel E, Simoni G, Lee Jv, Linhares RM, Silva PC.

Arq Bras Endocrinol Metabol. 2014 Oct;58(7):765-71.

19.
20.

Newborn screening for congenital adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: a retrospective population-based study.

Tsuji A, Konishi K, Hasegawa S, Anazawa A, Onishi T, Ono M, Morio T, Kitagawa T, Kashimada K.

BMC Pediatr. 2015 Dec 15;15:209. doi: 10.1186/s12887-015-0529-y.

Supplemental Content

Support Center